» Articles » PMID: 16405893

Type I and Type III Collagen Synthesis and Composition in the Valve Matrix in Aortic Valve Stenosis

Overview
Journal Atherosclerosis
Publisher Elsevier
Date 2006 Jan 13
PMID 16405893
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Changes in the collagenous matrix may contribute to the pathogenesis and progression of human aortic valve stenosis (AS). To evaluate the significance of collagen I and III in the pathogenesis of AS, we studied their synthesis in diseased valves. Type I and type III collagen mRNA expression and the immunohistochemical localization of the collagen antigens were studied from 36 AS and 2 normal aortic valves. The concentrations of propeptides and telopeptide structure of type I (PINP, PICP, and ICTP) and those of III collagens (PIIINP and IIINTP) were measured by radioimmunoassays in soluble tissue extracts and trypsin-solubilized calcified and non-calcified matrices of 11 AS and 24 healthy aortic valves of different ages. The synthesis of type I collagen, localized in the myofibroblasts adjacent to calcified nodules, was two- to three-fold in the AS samples compared to the controls. The proportion of collagen in the total protein fraction was 90% in the healthy valves, 50% in the non-calcified matrix, and 10% in the calcified matrix of AS valves. In the calcified valves, the ICTP content was six-fold compared to the age-matched controls and two-fold compared to the young control group. In the controls, the amount of ICTP in type I collagen decreased with age (r=-0.908, p<0.001) and was replaced by other cross-linked C-telopeptide structure. The concentration of type III collagen decreased during aging (r=-0.753, p<0.001). The decrease in total collagen content, despite the increase in type I collagen synthesis indicates an increase in collagen turnover in AS. The calcification of the aortic valves is accompanied by increased amount of ICTP in type I collagen.

Citing Articles

A three-dimensional valve-on-chip microphysiological system implicates cell cycle progression, cholesterol metabolism and protein homeostasis in early calcific aortic valve disease progression.

Tandon I, Woessner A, Ferreira L, Shamblin C, Vaca-Diez G, Walls A Acta Biomater. 2024; 186:167-184.

PMID: 39084496 PMC: 11702842. DOI: 10.1016/j.actbio.2024.07.036.


Aortic valve cell microenvironment: Considerations for developing a valve-on-chip.

Tandon I, Ozkizilcik A, Ravishankar P, Balachandran K Biophys Rev (Melville). 2024; 2(4):041303.

PMID: 38504720 PMC: 10903420. DOI: 10.1063/5.0063608.


The Role of Apoptosis and Oxidative Stress in a Cell Spheroid Model of Calcific Aortic Valve Disease.

Coutts C, Baldwin A, Jebeli M, Jolin G, Mungai R, Billiar K Cells. 2024; 13(1).

PMID: 38201249 PMC: 10778193. DOI: 10.3390/cells13010045.


Nuclear magnetic resonance spectroscopy to quantify major extracellular matrix components in fibro-calcific aortic valve disease.

Feistner L, Penk A, Bottner J, Buttner P, Thiele H, Huster D Sci Rep. 2023; 13(1):18823.

PMID: 37914797 PMC: 10620231. DOI: 10.1038/s41598-023-46143-7.


Integrated Analysis of LncRNA-Mediated ceRNA Network in Calcific Aortic Valve Disease.

Chen L, Wei K, Li J, Li Y, Cao H, Zheng Z Cells. 2022; 11(14).

PMID: 35883646 PMC: 9315639. DOI: 10.3390/cells11142204.